Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Dear Editor, With deep and durable responses seen in clinical trials, chimeric antigen receptor (CAR)-T cell therapy has transformed treatment outcomes for patients with relapsed/refractory multiple myeloma (RRMM) [1, 2]. Cytokine release syndrome (CRS), immune cell effector associated neurotoxicity syndrome (ICANS), cytopenias, and infections are common but manageable toxicities of CAR-T.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
